The Oncotype DX Test: For the Best-Informed Treatment Decision
The Oncotype DX tests are intended to be used for women recently diagnosed with either early-stage invasive breast cancer or DCIS (non-invasive) breast cancer. These unique genomic tests look at the activity of certain genes in your breast tumor tissue to provide personalized information that can help you and your doctor tailor treatment to your individual cancer. These pioneering genomic tests were developed to eliminate the “one-size-fits-all” approach to cancer treatment that often leads to the over-treatment or under-treatment of early-stage breast cancer.
If you have early-stage invasive breast cancer, the Oncotype DX Breast Recurrence Score test can tell you the likelihood that you may benefit from chemotherapy, as well as the chances of your breast cancer returning. If you have DCIS, the Oncotype DX Breast DCIS Score test can help to predict whether your cancer may come back in the same breast. Based on its ability to provide critical information for treatment decision making, the Oncotype DX Breast Recurrence Score test is recognized worldwide as standard of care for women with early-stage breast cancer.
-
Invasive Breast Cancer (Stage I-IIIa)
The Oncotype DX Breast Recurrence Score test predicts your response to chemotherapy as well as the chances of your cancer returning. This information can help you and your doctor make decisions about your care and increase confidence that your treatment is tailored for you.
-
DCIS Breast Cancer (Stage 0)
The Oncotype DX Breast DCIS Score test is the only genomic test available that helps women recently diagnosed with DCIS, or ductal carcinoma in situ. This information can help you and your doctor make decisions about your care and increase confidence that your treatment is tailored for you.
-
The Oncotype DX Breast Recurrence Score Test is Backed by Landmark Clinical Studies
Clinical validation studies are essential in the development of a genomic test. They help determine if the test is accurate by checking that the genes being analyzed actually relate to the presence or absence of disease. The Oncotype DX Breast Recurrence Score test has been validated in many such studies, showing that Recurrence Score results do correlate with risk of recurrence and chemotherapy benefit.
-
Oncotype DX Scores
Your Oncotype DX test results include your Recurrence Score or DCIS Score result. Your score can help you and your doctor choose what kind of treatment, if any, you should have after your surgery.
-
Insurance Coverage
Most insurance carriers cover the Oncotype DX test. In addition, Exact Sciences offers a program to help you secure access to the test.